Document is current
Any future updates will be listed below
-
Authors
Atreya, Mihir R.
Huang, Min
Moore, Andrew R.
Zheng, Hong
Hasin-Brumshtein, Yehudit
Fitzgerald, Julie C.
Weiss, Scott L.
Cvijanovich, Natalie Z.
Bigham, Michael T.
Jain, Parag N.
Schwarz, Adam J.
Lutfi, Riad
Nowak, Jeffrey
Thomas, Neal J.
Quasney, Michael
Dahmer, Mary K.
Baines, Torrey
Haileselassie, Bereketeab
Lautz, Andrew J.
Stanski, Natalja L.
Standage, Stephen W.
Kaplan, Jennifer M.
Zingarelli, Basilia
Sahay, Rashmi
Zhang, Bin
Sweeney, Timothy E.
Khatri, Purvesh
Sanchez-Pinto, L. Nelson
Kamaleswaran, Rishikesan
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (R21GM151703, R21GM150093, R21GM150093, R21GM151703, R21GM151703)
Cincinnati Children’s Research Foundation
National Heart, Lung, and Blood Institute (R01HL149910)
National Institute of Child Health and Human Development (R01HD105939)
- License Information
-
More Information
Article History
Received: 10 March 2024
Accepted: 5 July 2024
First Online: 17 July 2024
Declarations
:
: The study protocol was approved by Institutional Review Boards (IRBs) of the primary site (Cincinnati Children’s Hospital IR, Genomic Analysis of Pediatric Systemic Inflammatory Syndrome, IRB ID: 2008-0558) as well as all participating institutions. Informed consent was obtained from parent or guardian of patients. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review boards of participating institutions and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Cincinnati Children’s Hospital Medical Center (CCHMC) and the estate of the late Dr. Hector R. Wong hold patents for gene-expression-based pediatric septic shock endotypes, reflective of the host adaptive immune system. M.R.A and R.K hold a provisional patent for gene-expression-based multiple organ dysfunction syndrome (MODS) subclass identification, reflective of the host innate immune response. Inflammatix is a for-profit company focused on the development and commercialization of best-in-class host-response diagnostic tests. Y.H.B and T.E.S are employees and/or stockholders of Inflammatix Inc. P.K is a stockholder of Inflammatix Inc.
